NCT00439465 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Infusing Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF)post-Hematopoietic stem cell transplant (HSCT) Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
- id
- FG000
- title
- Ex-vivo Expanded Effector Cells
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 23
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 19
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Infusing Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF)post-Hematopoietic stem cell transplant (HSCT) Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
- id
- FG000
- title
- Ex-vivo Expanded Effector Cells
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 23
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 19
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle